News
OS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported first quarter 2025 financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback